Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies.
Fiche publication
Date publication
janvier 2022
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Pr BOUCHE Olivier, Pr GHIRINGHELLI François, Mme JACQUIN Marion, Dr VERNEREY Dewi, Dr VIENOT Angélique, Dr KAMINSKY Marie-Christine, Dr KIM Stephano, Mme MEURISSE Aurélia
Tous les auteurs :
Stouvenot M, Meurisse A, Saint A, Buecher B, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Smith D, Ghiringhelli F, Parzy A, de la Fouchardiere C, Almotlak H, Vienot A, Jacquin M, Taieb J, Nguyen T, Vernerey D, Borg C, Kim S
Lien Pubmed
Résumé
Squamous cell carcinoma of the anus (SCCA) is a rare disease often diagnosed at a localised stage. For locally advanced recurrence or metastatic disease, DCF (docetaxel, cisplatin, 5-fluorouracil) demonstrated high efficacy and became one of the standard regimens. However, there is no standard of care in the second line.
Mots clés
Advanced, Anal carcinoma, Chemotherapy, Metastatic, Second-line, Treatment
Référence
Eur J Cancer. 2022 Jan 4;162:138-147